☰

Ronald Hoffman - Publications

Affiliations: 
University of Illinois at Chicago, Health Sciences Center, Chicago, IL 60612, United States 
Area:
Cell Biology, Animal Physiology Biology, Medicine and Surgery
Tree Info Grants Similar researchers PubMed Report error

320 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Tremblay D, Schwartz M, Bakst R, Patel R, Schiano T, Kremyanskaya M, Hoffman R, Mascarenhas J. Modern management of splenomegaly in patients with myelofibrosis. Annals of Hematology. PMID 32417942 DOI: 10.1007/S00277-020-04069-4  0.327
2020 Zhou S, Tremblay D, Hoffman R, Kremyanskaya M, Najfeld V, Li L, Moshier E, Mascarenhas J. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms. Acta Haematologica. 1-9. PMID 32160610 DOI: 10.1159/000506146  0.343
2020 Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O'Connell C, Shammo J, Fleischman AG, Scherber RM, Mesa R, Yacoub A, Perkins C, Meckstroth S, Behlman L, Chiaramonte M, ... ... Hoffman R, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. PMID 32107559 DOI: 10.1182/Blood.2019003347  0.316
2020 Zimran E, Papa L, Djedaini M, Patel A, Iancu-Rubin C, Hoffman R. Expansion and preservation of the functional activity of adult hematopoietic stem cells cultured ex vivo with a histone deacetylase inhibitor. Stem Cells Translational Medicine. PMID 31950644 DOI: 10.1002/Sctm.19-0199  0.419
2019 Patel A, Clementelli CM, Jarocha D, Mosoyan G, Else C, Kintali M, Fong H, Tong J, Gordon R, Gillespie V, Keyzner A, Poncz M, Hoffman R, Iancu-Rubin C. Pre-clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in mice. Transfusion. 59: 3698-3713. PMID 31802511 DOI: 10.1111/Trf.15546  0.323
2019 Tremblay D, King A, Li L, Moshier E, Coltoff A, Koshy A, Kremyanskaya M, Hoffman R, Mauro MJ, Rampal RK, Mascarenhas J. Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leukemia & Lymphoma. 1-8. PMID 31711337 DOI: 10.1080/10428194.2019.1688323  0.308
2019 Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, ... ... Hoffman R, et al. . Blood. PMID 31515250 DOI: 10.1182/Blood.2019000428  0.34
2019 Nam AS, Kim KT, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND, Alonso A, Sheridan C, Mariani M, Dai X, Harrington E, ... ... Hoffman R, et al. Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature. PMID 31270458 DOI: 10.1038/S41586-019-1367-0  0.373
2019 Cimen Bozkus C, Roudko V, Finnigan JP, Mascarenhas J, Hoffman R, Iancu-Rubin C, Bhardwaj N. Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer Discovery. PMID 31266769 DOI: 10.1158/2159-8290.Cd-18-1356  0.345
2019 Papa L, Djedaini M, Hoffman R. Ex vivo HSC expansion challenges the paradigm of unidirectional human hematopoiesis. Annals of the New York Academy of Sciences. PMID 31199002 DOI: 10.1111/Nyas.14133  0.336
2019 Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, Mesa R, Petersen B, Farnoud N, Najfeld V, Rampal R, Dueck A, Hoffman R. Oral Idasanutlin in Patients with Polycythemia Vera. Blood. PMID 31167802 DOI: 10.1182/Blood.2018893545  0.391
2019 Papa L, Djedaini M, Hoffman R. Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid. Journal of Visualized Experiments : Jove. PMID 31033947 DOI: 10.3791/59532  0.429
2019 Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Malloy M, ... ... Hoffman R, et al. Impact of high molecular risk mutations on transplant outcomes in patients with myelofibrosis. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30625392 DOI: 10.1016/J.Bbmt.2019.01.002  0.341
2019 Bar-Natan M, Hoffman R. New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches. Haematologica. 104: 3-6. PMID 30598493 DOI: 10.3324/Haematol.2018.205989  0.314
2019 Dunbar A, Kosiorek HE, Krishnan A, McGovern E, Park Y, Patel MA, Weinberg RS, Yacoub A, Dueck AC, Mascarenhas J, Levine RL, Hoffman R, Rampal RK. Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials Blood. 134: 1661-1661. DOI: 10.1182/Blood-2019-129571  0.329
2019 Marcellino B, Tripodi J, Bar-Natan M, Fruchtman H, Farnoud N, Lu M, Kosiorek HE, Dueck AC, Rampal RK, Mascarenhas J, Najfeld V, Hoffman R. Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms Blood. 134: 4207-4207. DOI: 10.1182/Blood-2019-129565  0.379
2019 Lu M, Xia L, Hoffman R. A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells Blood. 134: 4201-4201. DOI: 10.1182/Blood-2019-129017  0.32
2019 Wang X, Rampal RK, Hu CS, Farnoud N, Famulare C, Patel MA, McGovern E, Hoffman R. The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells Blood. 134: 1677-1677. DOI: 10.1182/Blood-2019-128836  0.377
2019 Marcellino B, Cassinat B, Farnoud N, Lu M, Verger E, McGovern E, Patel MA, Kosiorek HE, Mehrotra M, Houldsworth J, Dueck AC, Rossi M, Kiladjian J, Rampal RK, Mascarenhas J, ... Hoffman R, et al. Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin Blood. 134: 838-838. DOI: 10.1182/Blood-2019-128342  0.378
2019 Papa L, Djedaini M, Schaniel C, Hoffman R. Distinct Mechanisms Underlying the Ex Vivo Expansion of Human Cord Blood Stem Cells with Different Strategies Currently Used for Allogeneic Transplantation Blood. 134: 4470-4470. DOI: 10.1182/Blood-2019-127040  0.338
2019 Hu CS, Huang F, Hoffman R, Wang X. Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells Blood. 134: 2963-2963. DOI: 10.1182/Blood-2019-126189  0.378
2019 Yacoub A, Mascarenhas J, Mesa RA, Kosiorek HE, Rampal RK, Silver RT, Salama ME, Siwoski O, Dueck AC, Sandy L, McMullin MF, Ewing J, O'Connell CL, Mead AJ, De Stefano V, ... ... Hoffman R, et al. Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings Blood. 134: 2943-2943. DOI: 10.1182/Blood-2019-124865  0.315
2019 Kucine N, Bergmann S, Krichevsky S, Jones D, Rytting ME, Resar L, Mascarenhas J, Verstovsek S, Hoffman R. Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms Blood. 134: 4194-4194. DOI: 10.1182/Blood-2019-124023  0.302
2019 Bozkus CC, Roudko V, Finnigan JP, Mascarenhas J, Hoffman R, Iancu-Rubin C, Bhardwaj N. Abstract B072: Immune checkpoint blockade enhances mutated calreticulin-induced T-cell immunity in myeloproliferative neoplasms Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-B072  0.362
2018 Marcellino BK, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J, Rampal RK, Dueck A, Najfeld V. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Advances. 2: 3581-3589. PMID 30563882 DOI: 10.1182/Bloodadvances.2018024018  0.309
2018 Rampal RK, Mascarenhas JO, Kosiorek HE, Price L, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Menghrajani K, Najfeld V, Sandy L, Heaney ML, Levine RL, ... ... Hoffman R, et al. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. Blood Advances. 2: 3572-3580. PMID 30563881 DOI: 10.1182/Bloodadvances.2018019661  0.345
2018 Papa L, Zimran E, Djedaini M, Ge Y, Ozbek U, Sebra R, Sealfon SC, Hoffman R. Ex vivo human HSC expansion requires coordination of cellular reprogramming with mitochondrial remodeling and p53 activation. Blood Advances. 2: 2766-2779. PMID 30348672 DOI: 10.1182/Bloodadvances.2018024273  0.4
2018 Zimran E, Keyzner A, Iancu-Rubin C, Hoffman R, Kremyanskaya M. Novel treatments to tackle myelofibrosis. Expert Review of Hematology. 1-14. PMID 30324817 DOI: 10.1080/17474086.2018.1536538  0.359
2018 Wang X, Hu CS, Petersen B, Qiu J, Ye F, Houldsworth J, Eng K, Huang F, Hoffman R. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Advances. 2: 2378-2388. PMID 30242099 DOI: 10.1182/Bloodadvances.2018022012  0.477
2018 Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, ... ... Hoffman R, et al. Ruxolitinib Therapy Followed by Reduced Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis - Myeloproliferative Disorders Research Consortium 114 study. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30205231 DOI: 10.1016/J.Bbmt.2018.09.001  0.35
2018 Lancman G, Brunner A, Hoffman R, Mascarenhas J, Hobbs G. Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. Leukemia Research. 70: 49-55. PMID 29807273 DOI: 10.1016/J.Leukres.2018.05.004  0.342
2018 Qiu J, Salama ME, Hu CS, Li Y, Wang X, Hoffman R. The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Advances. 2: 1130-1145. PMID 29776986 DOI: 10.1182/Bloodadvances.2017015073  0.349
2018 Gnanapragasam MN, Crispino JD, Ali AM, Weinberg R, Hoffman R, Raza A, Bieker JJ. Survey and evaluation of mutations in the human KLF1 transcription unit. Scientific Reports. 8: 6587. PMID 29700354 DOI: 10.1038/S41598-018-24962-3  0.319
2018 Zimran E, Hoffman R, Kremyanskaya M. Current approaches to challenging scenarios in myeloproliferative neoplasms. Expert Review of Anticancer Therapy. 18: 567-578. PMID 29575945 DOI: 10.1080/14737140.2018.1457441  0.369
2018 Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. PMID 29515238 DOI: 10.1038/S41375-018-0077-1  0.378
2018 Nam AS, Kim K, Chaligne R, Izzo F, Ang C, Omans N, Pastore A, Taylor J, Alonso A, Tam W, Hoffman R, Scandura J, Rabadan R, Abdel-Wahab OI, Smibert P, et al. High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations Blood. 132: 541-541. DOI: 10.1182/Blood-2018-99-119236  0.413
2018 Kremyanskaya M, Hoffman R, Mascarenhas J, Verstovsek S, Mertz J, Garner F, Senderowicz A. A Phase 2 Study of Cpi-0610, a Bromodomain and Extraterminal (BET) Inhibitor, in Patients with Myelofibrosis (MF) Blood. 132: 5481-5481. DOI: 10.1182/Blood-2018-99-119157  0.352
2018 Patel A, Kintali M, Mosoyan G, Hoffman R, Iancu-Rubin C. Infusion of a Cryopreservable Human Megakaryocyte-Biased Cell Product Results in Sustained Platelet Reconstitution In Vivo Blood. 132: 117-117. DOI: 10.1182/Blood-2018-99-118682  0.319
2018 Wang X, Hu CS, Tripodi J, Najfeld V, Petersen B, Rampal RK, Farnoud N, Famulare C, Mascarenhas J, Hoffman R. Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Hematopoietic Stem Cells Blood. 132: 101-101. DOI: 10.1182/Blood-2018-99-117348  0.439
2018 Lu M, Xia L, Salama ME, Hoffman R. Enriched Populations of Human Megakaryocytic Cells Affect the Behavior of Myelofibrosis CD34+ Cells As Well As Cells Belonging to the MF Supportive Microenvironment Blood. 132: 3057-3057. DOI: 10.1182/Blood-2018-99-117062  0.377
2018 Varricchio L, Mascarenhas J, Migliaccio AR, O'Connor-McCourt M, Tremblay G, Denis J, Iancu-Rubin C, Hoffman R. AVID200, a Potent Trap for TGF-β Ligands Inhibits TGF-β1 Signaling in Human Myelofibrosis Blood. 132: 1791-1791. DOI: 10.1182/Blood-2018-99-116474  0.376
2018 Mascarenhas J, Komrokji RS, Cavo M, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Bussolari J, Zhu E, Huang F, Rose E, Sherman L, et al. Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels Blood. 132: 685-685. DOI: 10.1182/Blood-2018-99-115163  0.334
2018 Lancman G, Miller K, Li S, Ho VT, Fathi AT, Chen Y, Keyzner A, Tremblay D, Geevarghese A, Chatterjee P, Hoffman R, Mascarenhas J, Hobbs GS. The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis Blood. 132: 5784-5784. DOI: 10.1182/Blood-2018-99-112769  0.363
2018 Rampal RK, Mascarenhas J, Kosiorek HE, Bhave R, Hexner EO, Wang ES, Gerds AT, Heaney ML, Abboud CN, Kremyanskaya M, Berenzon D, Odenike O, Virtgaym E, Sandy L, Weinberg RS, ... ... Hoffman R, et al. Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial) Blood. 132: 3027-3027. DOI: 10.1182/Blood-2018-99-111935  0.333
2018 Wang W, Wang T, Kotini AG, Iancu-Rubin C, Hoffman R, Papapetrou EP. Modeling Calreticulin-Mutant Myeloproliferative Neoplasms with Isogenic Induced Pluripotent Stem Cells Blood. 132: 4319-4319. DOI: 10.1182/Blood-2018-99-111512  0.326
2017 Gowin K, Kosiorek H, Dueck A, Mascarenhas J, Hoffman R, Reeder C, Camoriano J, Tibes R, Gano K, Palmer J, Mesa R. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leukemia Research. 60: 31-35. PMID 28646676 DOI: 10.1016/J.Leukres.2017.06.005  0.366
2017 Mosoyan G, Kraus T, Ye F, Eng K, Crispino JD, Hoffman R, Iancu-Rubin C. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis. Leukemia. PMID 28270692 DOI: 10.1038/Leu.2017.78  0.383
2017 Psaila B, Heuston EF, Milojkovic D, Lichtenberg J, Anderson SM, Hoffman R, Roberts I, Mead AJ, Bodine DM, Program NCS, Barkas N. A Single-Cell Approach to Unraveling Abnormal Megakaryocyte Differentiation and Function in Myelofibrosis Blood. 130: 490-490. DOI: 10.1182/Blood.V130.Suppl_1.490.490  0.43
2017 Dueck AC, Mascarenhas J, Kosiorek HE, Yacoub A, Prchal JT, Berenzon D, Baer MR, Ritchie EK, Silver RT, Kessler CM, Winton EF, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz DS, ... ... Hoffman R, et al. Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial Blood. 130: 4206-4206. DOI: 10.1182/Blood.V130.Suppl_1.4206.4206  0.327
2017 Bozkus CC, Finnigan JP, Mascarenhas J, Hoffman R, Bhardwaj N, Iancu-Rubin C. Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms Blood. 130: 384-384. DOI: 10.1182/Blood.V130.Suppl_1.384.384  0.365
2017 Yacoub A, Mascarenhas J, Kosiorek HE, Prchal JT, Berenzon D, Baer MR, Ritchie EK, Silver RT, Kessler CM, Winton EF, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz DS, Rondelli D, ... ... Hoffman R, et al. Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial Blood. 130: 321-321. DOI: 10.1182/Blood.V130.Suppl_1.321.321  0.351
2017 Coltoff A, Tremblay D, Kremyanskaya M, Hoffman R, Mascarenhas J. Real-World Outcomes of Ruxolitinib for Polycythemia Vera Blood. 130: 2926-2926. DOI: 10.1182/Blood.V130.Suppl_1.2926.2926  0.364
2017 Mascarenhas J, Lu M, Virtgaym E, Kosiorek H, Stal M, Sandy L, Orellana A, Xia L, Kremyanskaya M, Petersen B, Dueck A, Hoffman R. Open Label Phase I Study of Single Agent Oral RG7388 (idasanutlin) in Patients with Polycythemia Vera and Essential Thrombocythemia Blood. 130: 254-254. DOI: 10.1182/Blood.V130.Suppl_1.254.254  0.338
2017 Virtgaym E, Tremblay D, Iancu-Rubin C, Hoffman R, Mascarenhas J. Imetelstat for treatment of myelofibrosis Expert Opinion On Orphan Drugs. 5: 91-97. DOI: 10.1080/21678707.2017.1266934  0.348
2016 Mascarenhas J, Sandy L, Lu M, Yoon J, Petersen B, Zhang D, Ye F, Newsom C, Najfeld V, Hochman T, Goldberg JD, Hoffman R. A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leukemia Research. 53: 13-19. PMID 27930945 DOI: 10.1016/J.Leukres.2016.11.015  0.348
2016 Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner AR, Coughlin P, Winton E, Burn TC, O'Neill P, Clark J, Hunter D, Assad A, Hoffman R, et al. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. PMID 27789678 DOI: 10.3324/Haematol.2016.151126  0.335
2016 Chen Y, Shan Y, Lu M, DeSouza N, Guo Z, Hoffman R, Liang AB, Li S. Genetic and Pharmacologic Targeting of Alox5 Attenuates JAK2V617F Induced Polycythemia Vera in Mice. Cancer Research. PMID 27784744 DOI: 10.1158/0008-5472.Can-15-2933  0.367
2016 Keyzner A, Han S, Shapiro S, Moshier E, Schorr E, Petersen B, Najfeld V, Kremyanskaya M, Isola L, Hoffman R, Mascarenhas J. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27596130 DOI: 10.1016/J.Bbmt.2016.08.029  0.355
2016 Ceglia I, Dueck AC, Masiello F, Martelli F, He W, Federici G, Petricoin EF, Zeuner A, Iancu-Rubin C, Weinberg R, Hoffman R, Mascarenhas J, Rita Migliaccio A. Pre-clinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis. Experimental Hematology. PMID 27592389 DOI: 10.1016/J.Exphem.2016.08.007  0.381
2016 Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, Hoffman R, Mascarenhas J. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 101: 660-71. PMID 27252511 DOI: 10.3324/Haematol.2015.141283  0.334
2016 Wang X, Haylock D, Hu CS, Kowalczyk W, Jiang T, Qiu J, Mosoyan G, He W, Marshall N, Mascarenhas J, Tarasova A, Brody J, Winkler D, Hoffman R. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. Blood. PMID 27114459 DOI: 10.1182/Blood-2015-10-674465  0.434
2016 Khan I, Shergill A, Saraf SL, Chen YF, Patel PR, Quigley JG, Peace D, Gordeuk VR, Hoffman R, Rondelli D. Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma & Leukemia. PMID 27052852 DOI: 10.1016/J.Clml.2016.02.036  0.314
2016 Lu M, Xia L, Salama ME, Hoffman R. Splenic Micro Environmental Cells from Patients with Myelofibrosis Elaborate a Cascade of Cytokines and Serve As a Niche for Malignant Hematopoiesis Blood. 128: 953-953. DOI: 10.1182/Blood.V128.22.953.953  0.39
2016 Wang X, Hu CS, Qiu J, Hoffman R. The Thrombopoietin Receptor (MPL) Is a Selective Marker for the Identification of Hematopoietic Stem Cells from Myelofibrosis Patients Blood. 128: 950-950. DOI: 10.1182/Blood.V128.22.950.950  0.417
2016 Iancu-Rubin C, Fong H, Mosoyan G, Patel A, Sabado R, Marcia M, Moshier E, Ozbek U, Keyzner A, Bhardwaj N, McNiece IK, Tong J, Hoffman R. Preclinical Development of a Cord Blood (CB)-Derived Hematopoietic Stem Cell (HSC) Product for Allogeneic Transplantation in Patients with Hematological Malignancies Blood. 128: 818-818. DOI: 10.1182/Blood.V128.22.818.818  0.416
2016 Mascarenhas JO, Prchal JT, Rambaldi A, Mesa RA, Berenzon D, Yacoub A, Harrison CN, McMullin MF, Vannucchi AM, Ewing JC, O'Connell CL, Kiladjian J, Mead A, Winton EF, Leibowitz DS, ... ... Hoffman R, et al. Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia Blood. 128: 479-479. DOI: 10.1182/Blood.V128.22.479.479  0.34
2016 Fong H, Mosoyan G, Patel A, Hoffman R, Tong J, Iancu-Rubin C. Preclinical Development of a Cryopreservable Megakaryocyte Cell Product from Cord Blood Derived Hematopoietic Stem Cells Blood. 128: 3859-3859. DOI: 10.1182/Blood.V128.22.3859.3859  0.413
2016 Papa L, Zimran E, Djedaini M, Hoffman R. Valproic Acid Expands the Numbers of HSCs from Cord Blood CD34+ Cells By Linking Epigenetic Modifications to Mitochondrial Remodeling and p53 Upregulation Blood. 128: 369-369. DOI: 10.1182/Blood.V128.22.369.369  0.406
2016 Rampal RK, Tamari R, Zhang N, McNamara CJ, Rapaport F, Litvin R, Maloy MA, Castro-Malaspina H, Giralt S, Weinberg RS, Mascarenhas J, Mesa RA, Rondelli D, Dueck AC, Levine RL, ... ... Hoffman R, et al. Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Blood. 128: 2301-2301. DOI: 10.1182/Blood.V128.22.2301.2301  0.349
2016 Reading NS, Agarwal AM, Hoffman R, Prchal JT, Salama ME. Transcriptional Characterization of Myelofibrotic Bone Marrow Microenvironment Reveals Distinct Tumor Microenvironment in JAK2+ and Calr+ PMF Marrows Blood. 128: 1954-1954. DOI: 10.1182/Blood.V128.22.1954.1954  0.379
2016 Gupta V, Kosiorek HE, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Mesa RA, Tognoni G, Prosperini G, Di Lelio A, Serone E, Marfisi L, Orellano A, Potiphar L, Salama ME, ... ... Hoffman R, et al. Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC) Blood. 128: 1126-1126. DOI: 10.1182/Blood.V128.22.1126.1126  0.357
2016 Rampal RK, Mascarenhas JO, Kosiorek HE, Berenzon D, Hexner E, Abboud CN, Kremyanskaya M, Weinberg RS, Salama ME, Tognoni G, Prosperini G, Di Lelio A, Serone E, Marfisi L, Sandy L, ... ... Hoffman R, et al. Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial) Blood. 128: 1124-1124. DOI: 10.1182/Blood.V128.22.1124.1124  0.352
2015 Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, ... Hoffman R, et al. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26324368 DOI: 10.1200/Jco.2015.61.6474  0.32
2015 Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, ... ... Hoffman R, et al. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell. 28: 15-28. PMID 26175413 DOI: 10.1016/J.Ccell.2015.06.006  0.321
2015 Iancu-Rubin C, Hoffman R. Role of epigenetic reprogramming in hematopoietic stem cell function. Current Opinion in Hematology. 22: 279-85. PMID 26049747 DOI: 10.1097/Moh.0000000000000143  0.388
2015 Lu M, Xia L, Liu YC, Hochman T, Bizzari L, Aruch D, Lew J, Weinberg R, Goldberg JD, Hoffman R. Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood. PMID 26022238 DOI: 10.1182/Blood-2014-12-618595  0.421
2015 Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Bone Marrow Transplantation. 50: 628-36. PMID 25665047 DOI: 10.1038/Bmt.2014.323  0.325
2015 Hexner EO, Mascarenhas J, Prchal J, Roboz GJ, Baer MR, Ritchie EK, Leibowitz D, Demakos EP, Miller C, Siuty J, Kleczko J, Price L, Jeschke G, Weinberg R, Basu T, ... ... Hoffman R, et al. Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leukemia & Lymphoma. 1-9. PMID 25563429 DOI: 10.3109/10428194.2014.1001986  0.324
2015 Verstovsek S, Hoffman R, Mascarenhas J, Soria JC, Bahleda R, McCoon P, Tang W, Cortes J, Kantarjian H, Ribrag V. A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leukemia Research. 39: 157-63. PMID 25530567 DOI: 10.1016/J.Leukres.2014.11.018  0.327
2015 Wang X, Cho SY, Hu CS, Chen D, Roboz J, Hoffman R. C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Experimental Hematology. 43: 100-9.e1. PMID 25461253 DOI: 10.1016/J.Exphem.2014.10.013  0.374
2015 Falchi M, Varricchio L, Masiello F, Tafuri A, Girelli G, Iancu-Rubin C, Hoffman R, Migliaccio AR. The JAK2V617F mutation disrupts the regulated association between calreticulin and the glucocorticoid receptor observed in normal erythroid cells Italian Journal of Anatomy and Embryology. 120: 105. DOI: 10.13128/Ijae-16966  0.395
2015 Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas JO, Ritchie EK, Hoffman R, Silver RT, Kremyanskaya M, Pozdnyakova O, Hasserjian RP, Trehu E, Salama ME, Kantarjian HM, Gotlib J. PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks Blood. 126: 56-56. DOI: 10.1182/Blood.V126.23.56.56  0.321
2015 Falchi M, Varricchio L, Martelli F, Masiello F, Piccioni O, Tafuri A, Girelli G, Iancu-Rubin C, Hoffman R, Migliaccio AR. The JAK2 V617F Mutation Disrupts the Regulatory Activity Exerted By Calreticulin on the Glucocorticoid Receptor in Erythroid Cells Blood. 126: 5216-5216. DOI: 10.1182/Blood.V126.23.5216.5216  0.361
2015 Migliaccio AR, Iancu-Rubin C, Weinberg RS, Hoffman R, Dueck AC, Mascarenhas JO. An Inhibitor of TGF-β Promotes Proliferation of Normal but Not MPN Hematopoietic Cells and Is a Candidate Therapeutic Agent for the Treatment of MPN Patients Carrying JAK2 V617F or Calr pQ365fs Mutations Blood. 126: 4089-4089. DOI: 10.1182/Blood.V126.23.4089.4089  0.379
2015 Qiu J, Wang X, Salama ME, Hoffman R. Characterization and Isolation of Splenic Littoral Cells, a Possible Cellular Niche for Extramedullary Hematopoiesis in Myelofibrosis Blood. 126: 3594-3594. DOI: 10.1182/Blood.V126.23.3594.3594  0.351
2015 Reading NS, Prchal JT, Hoffman R, Salama ME. Digital Immune Expression Profiling Coupled with Immunohistochemistry for Interrogation of Microenvironment in Formalin Fixed Paraffin Embedded Specimens of Marrow and Spleen from PMF Patients Blood. 126: 2832-2832. DOI: 10.1182/Blood.V126.23.2832.2832  0.371
2015 Gowin KL, Kosiorek HE, Dueck AC, Mascarenhas J, Hoffman R, Reeder CB, Camoriano J, Fauble V, Tibes R, Gano K, Ghurye V, Koenig P, Mesa RA. Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis Blood. 126: 1618-1618. DOI: 10.1182/Blood.V126.23.1618.1618  0.331
2015 Verstovsek S, Pozdnyakova O, Hasserjian R, Salama M, Mesa R, Foltz L, Gupta V, Mascarenhas J, Ritchie E, Hoffman R, Silver R, Kremyanskaya M, Trehu E, Kantarjian H, Gotlib J. Outcomes in Myelofibrosis Patients Completing 24 and 36 Weeks of Treatment with PRM-151 Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.119  0.359
2014 Wang X, Ye F, Tripodi J, Hu CS, Qiu J, Najfeld V, Novak J, Li Y, Rampal R, Hoffman R. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. Blood. 124: 2987-95. PMID 25193869 DOI: 10.1182/Blood-2014-02-558015  0.441
2014 Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, ... ... Hoffman R, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 124: 1183-91. PMID 24963042 DOI: 10.1182/Blood-2014-04-572545  0.367
2014 Lu M, Xia L, Li Y, Wang X, Hoffman R. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. Blood. 124: 771-9. PMID 24869939 DOI: 10.1182/Blood-2013-11-536854  0.383
2014 Chaurasia P, Gajzer DC, Schaniel C, D'Souza S, Hoffman R. Epigenetic reprogramming induces the expansion of cord blood stem cells. The Journal of Clinical Investigation. 124: 2378-95. PMID 24762436 DOI: 10.1172/Jci70313  0.394
2014 Iancu-Rubin C, Mosoyan G, Glenn K, Gordon RE, Nichols GL, Hoffman R. Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. Experimental Hematology. 42: 137-45.e5. PMID 24309210 DOI: 10.1016/J.Exphem.2013.11.012  0.306
2014 Malhotra J, Kremyanskaya M, Schorr E, Hoffman R, Mascarenhas J. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. Clinical Lymphoma, Myeloma & Leukemia. 14: 31-6. PMID 24220620 DOI: 10.1016/J.Clml.2013.09.015  0.379
2014 Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas J, Ritchie EK, Hoffman R, Silver RT, Hong W, Kremyanskaya M, Trehu EG, Kantarjian HM, Gotlib JR. Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results. Journal of Clinical Oncology. 32: 7114-7114. DOI: 10.1200/Jco.2014.32.15_Suppl.7114  0.354
2014 Wang X, Haylock D, Hu CS, Mosoyan G, Winkler D, Hoffman R. A thrombopoietin antagonist is capable of affecting stem and progenitor cells of patients with myelofibrosis Blood. 124: 819-819. DOI: 10.1182/Blood.V124.21.819.819  0.414
2014 Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner R, Coughlin P, Winton E, Hunter D, Assad A, Clark J, O'Neill P, Hoffman R, Verstovsek S. Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis Blood. 124: 714-714. DOI: 10.1182/Blood.V124.21.714.714  0.326
2014 Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas JO, Ritchie EK, Hoffman R, Silver RT, Kremyanskaya M, Pozdnyakova O, Hasserjian RP, Trehu E, Kantarjian HM, Gotlib JR. Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results Blood. 124: 713-713. DOI: 10.1182/Blood.V124.21.713.713  0.319
2014 Iancu-Rubin C, Mosoyan G, Parker CC, Eng K, Hoffman R. Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Malignant Megakaryopoiesis in Myeloproliferative Neoplasms (MPN) Blood. 124: 4582-4582. DOI: 10.1182/Blood.V124.21.4582.4582  0.421
2014 Gowin KL, Dueck AC, Mascarenhas JO, Hoffman R, Reeder CB, Camoriano J, Gano K, Ghurye V, Nagi Reddy S, Koenig P, Fauble V, Tibes R, Mesa R. Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia Blood. 124: 3206-3206. DOI: 10.1182/Blood.V124.21.3206.3206  0.387
2014 Wang X, Hu CS, Li Y, Hoffman R. Thrombopoietin Affects the Behavior of Myelofibrosis Stem Cells Blood. 124: 2145-2145. DOI: 10.1182/Blood.V124.21.2145.2145  0.416
2014 Wang X, Hu CS, Li Y, Qiu J, Lam M, Eng K, Hoffman R. Effects of Imetelstat on CD34+ Cells of Patients with Myelofibrosis Blood. 124: 1879-1879. DOI: 10.1182/Blood.V124.21.1879.1879  0.398
2014 Lu M, Xia L, Liu Y, Hochman T, Weinberg RS, Goldberg JD, Hoffman R. The Effects of Lipocalin (LCN2) on Hematopoiesis in Primary Myelofibrosis Blood. 124: 1878-1878. DOI: 10.1182/Blood.V124.21.1878.1878  0.452
2014 Najfeld V, Tripodi J, Wang X, Schwartz M, Kremyanskaya M, Cytryn E, Zirkiev S, Rampal RK, Mascarenhas JO, Hoffman R. Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression Blood. 124: 1871-1871. DOI: 10.1182/Blood.V124.21.1871.1871  0.385
2013 Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman R. Advances in myelofibrosis: a clinical case approach. Haematologica. 98: 1499-509. PMID 24091929 DOI: 10.3324/Haematol.2013.086348  0.398
2013 Mesa RA, Silver RT, Verstovsek S, Mascarenhas J, Kessler CM, Rondelli D, Goldberg JD, Marchioli R, Demakos EP, Silverman LR, Hoffman R. Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. Haematologica. 98: 1421-3. PMID 23812932 DOI: 10.3324/Haematol.2012.083337  0.31
2013 Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 121: 4832-7. PMID 23570800 DOI: 10.1182/Blood-2013-02-482232  0.34
2013 Lew J, Frucht SJ, Kremyanskaya M, Hoffman R, Mascarenhas J. Hemichorea in a patient with JAK2V617F blood cells Blood. 121: 1239-1240. PMID 23411735 DOI: 10.1182/Blood-2012-12-468751  0.36
2013 Wang X, Tripodi J, Kremyanskaya M, Blouin A, Roda P, Hoffman R, Najfeld V. BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. Blood. 121: 1238-9. PMID 23411734 DOI: 10.1182/Blood-2012-11-467787  0.33
2013 Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, Goldberg JD, Hoffman R. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). British Journal of Haematology. 161: 68-75. PMID 23330839 DOI: 10.1111/Bjh.12220  0.35
2013 Iancu-Rubin C, Mosoyan G, Wang J, Kraus T, Sung V, Hoffman R. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Experimental Hematology. 41: 155-166.e17. PMID 23261964 DOI: 10.1016/J.Exphem.2012.12.002  0.397
2013 Mascarenhas J, Talpaz M, Gupta V, Savona M, Coughlin P, Winton E, Hunter D, Mookerjee B, Leopold L, Clark J, O'Neill P, Ccrp, Hoffman R, Verstovsek S. An Open-Label, Phase II Study Of The JAK1 Inhibitor INCB039110 In Patients With Myelofibrosis Blood. 122: 663-663. DOI: 10.1182/Blood.V122.21.663.663  0.33
2013 Tripodi J, Najfeld V, Lu M, Hoffman R. Characterization Of Splenic Fibroblasts From Patients With Myelofibrosis Blood. 122: 4107-4107. DOI: 10.1182/Blood.V122.21.4107.4107  0.426
2013 Wang X, Cho SY, Chen D, Roboz J, Hoffman R. An Altered Microenvironment Within The Spleens Of Patients With Myelofibrosis Affects CD34+ Cell Trafficking Blood. 122: 2848-2848. DOI: 10.1182/Blood.V122.21.2848.2848  0.394
2013 Lu M, Yoo S, Xia L, Wang X, Li Y, Zhu J, Hoffman R. Interferon α Has Varied Effects On CD34+ Cells From Patients With Polycythemia Vera Blood. 122: 2840-2840. DOI: 10.1182/Blood.V122.21.2840.2840  0.379
2013 Xia L, Weinberg RS, Hoffman R. Neutophil Gelatinase –Associated Lipocalin (LCN2) Affects Primary Melofibrosis Hematopoietic Progenitor Cells As Well As Microenvironmental Cells Blood. 122: 2839-2839. DOI: 10.1182/Blood.V122.21.2839.2839  0.44
2012 Wang X, Prakash S, Lu M, Tripodi J, Ye F, Najfeld V, Li Y, Schwartz M, Weinberg R, Roda P, Orazi A, Hoffman R. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. The Journal of Clinical Investigation. 122: 3888-99. PMID 23023702 DOI: 10.1172/Jci64397  0.45
2012 Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R, Ravandi F, Petersen B, Roboz G, Feldman E, Podoltsev N, Douer D, Levine R, Tallman M, Hoffman R, et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia Research. 36: 1500-4. PMID 22938832 DOI: 10.1016/J.Leukres.2012.08.013  0.311
2012 Lu M, Wang X, Li Y, Tripodi J, Mosoyan G, Mascarenhas J, Kremyanskaya M, Najfeld V, Hoffman R. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 120: 3098-105. PMID 22872685 DOI: 10.1182/Blood-2012-02-410712  0.357
2012 Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 120: 1367-79. PMID 22700718 DOI: 10.1182/Blood-2012-05-399048  0.369
2012 Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3008-14. PMID 22474318 DOI: 10.1158/1078-0432.Ccr-11-3145  0.392
2012 Kremyanskaya M, Mascarenhas J, Hoffman R. Why does my patient have erythrocytosis? Hematology/Oncology Clinics of North America. 26: 267-83, vii-viii. PMID 22463827 DOI: 10.1016/J.Hoc.2012.02.011  0.379
2012 Prakash S, Hoffman R, Barouk S, Wang YL, Knowles DM, Orazi A. Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 815-27. PMID 22388763 DOI: 10.1038/Modpathol.2012.33  0.315
2012 Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas J, Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Experimental Hematology. 40: 564-74. PMID 22381681 DOI: 10.1016/J.Exphem.2012.02.004  0.335
2012 Chaurasia P, Gajzer D, Feldman M, Hoffman R. Histone Deacetylase Inhibitors Promote the Ex Vivo Expansion of Cord Blood CD34+ Cells in Serum Free Cultures Accompanied by the Upregulation of Pluripotency Genes Blood. 120: 345-345. DOI: 10.1182/Blood.V120.21.345.345  0.341
2012 Lu M, Wang X, Mosoyan G, Li Y, Hoffman R. Combination Treatment with RG7112 and Pegylated Interferon α 2a Specifically Targets JAK2V617F Positive Progenitor Cells From Patients with Myeloproliferative Neoplasms. Blood. 120: 2865-2865. DOI: 10.1182/Blood.V120.21.2865.2865  0.407
2012 Iancu-Rubin C, Mosoyan G, Wang J, Kraus T, Hoffman R. Stromal Cells-Mediated Inhibition of Erythropoiesis Can Be Counteracted by Sotatercept (ACE-011), an Activin Receptor Type II (ActRIIA) Fusion Protein Blood. 120: 1254-1254. DOI: 10.1182/Blood.V120.21.1254.1254  0.407
2012 Smith EL, Schuchman E, Hoffman R. Abstract LB-165: The role of sphingolipid metabolism in the treatment of acute myeloid leukemia Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-165  0.347
2011 Mascarenhas J, Roper N, Chaurasia P, Hoffman R. Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clinical Epigenetics. 2: 197-212. PMID 22704337 DOI: 10.1007/S13148-011-0050-6  0.323
2011 Sozer S, Hoffman R. Laser-capture microdissection and analysis of liver endothelial cells from patients with Budd-Chiari syndrome. Methods in Molecular Biology (Clifton, N.J.). 755: 405-15. PMID 21761323 DOI: 10.1007/978-1-61779-163-5_34  0.393
2011 Najfeld V, Wisch N, Mascarenhas J, Issa L, Tripodi J, Sidhu M, Hoffman R. Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression. Cancer Genetics. 204: 165-70. PMID 21504717 DOI: 10.1016/J.Cancergencyto.2010.09.001  0.323
2011 Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 117: 4706-15. PMID 21389325 DOI: 10.1182/Blood-2010-08-258772  0.39
2011 Varricchio L, Masselli E, Alfani E, Battistini A, Migliaccio G, Vannucchi AM, Zhang W, Rondelli D, Godbold J, Ghinassi B, Whitsett C, Hoffman R, Migliaccio AR. The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood. 118: 425-36. PMID 21355091 DOI: 10.1182/Blood-2010-07-296921  0.334
2011 Chaurasia P, Berenzon D, Hoffman R. Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. Blood. 117: 4632-41. PMID 21355088 DOI: 10.1182/Blood-2010-10-314567  0.395
2011 Lu M, Tripodi J, Li Y, Wang X, Najfeld V, Mascarenhas J, Hoffman R. Treatment with Nutlin-3, a Small-Molecule Antagonist of MDM2, in Combination with Low Doses of Pegylated Interferon Alpha 2a Targets Hematopoietic Progenitor Cells From Polycythemia Vera (PV) Patients Blood. 118: 796-796. DOI: 10.1182/Blood.V118.21.796.796  0.426
2011 Mascarenhas J, Mercado A, Rodriguez A, Lu M, Kalvin C, Li X, Petersen B, Najfeld V, Goldberg JD, Hoffman R. Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibtor, Panobinostat (LBH589), in Patients with Myelofibrosis Blood. 118: 794-794. DOI: 10.1182/Blood.V118.21.794.794  0.374
2011 Iancu-Rubin C, Gajzer D, Mosoyan G, Mascarenhas J, Hoffman R. Panobinostat (LBH589)-Mediated Acetylation of Tubulin Plays a Role in Megakaryocyte Maturation and Platelet Release Blood. 118: 704-704. DOI: 10.1182/Blood.V118.21.704.704  0.389
2011 Nieto MJ, Scigliano E, Grosskreutz CL, Fruchtman S, Mascarenhas J, Osman K, Malone A, Cytryn S, Najfeld V, Hoffman R, Isola L. Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis Blood. 118: 4534-4534. DOI: 10.1182/Blood.V118.21.4534.4534  0.39
2011 Wang X, Prakash S, Lu M, Li Y, Orazi A, Hoffman R. Characterization of Splenic CD34+ Cells From Patients with Primary Myelofibrosis Blood. 118: 2810-2810. DOI: 10.1182/Blood.V118.21.2810.2810  0.392
2011 Rondelli D, Goldberg JD, Marchioli R, Isola L, Shore TB, Prchal JT, Bacigalupo A, Rambaldi A, Klisovic RB, Gupta V, Andreasson B, Demakos EP, Price LS, Scarano M, Wetzler M, ... ... Hoffman R, et al. Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis Blood. 118: 1750-1750. DOI: 10.1182/Blood.V118.21.1750.1750  0.37
2010 Tripodi J, Hoffman R, Najfeld V, Weinberg R. Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer Management and Research. 2: 219-23. PMID 21188113 DOI: 10.2147/Cmr.S12829  0.31
2010 Mascarenhas J, Hoffman R. Myeloproliferative neoplasms: new translational therapies. The Mount Sinai Journal of Medicine, New York. 77: 667-83. PMID 21105128 DOI: 10.1002/Msj.20225  0.321
2010 Wang X, Zhang W, Tripodi J, Lu M, Xu M, Najfeld V, Li Y, Hoffman R. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood. 116: 5972-82. PMID 20858855 DOI: 10.1182/Blood-2010-02-269696  0.425
2010 Mascarenhas J, Navada S, Malone A, Rodriguez A, Najfeld V, Hoffman R. Therapeutic options for patients with myelofibrosis in blast phase. Leukemia Research. 34: 1246-9. PMID 20627294 DOI: 10.1016/J.Leukres.2010.05.008  0.384
2010 Lu M, Wang J, Li Y, Berenzon D, Wang X, Mascarenhas J, Xu M, Hoffman R. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood. 116: 4284-7. PMID 20625010 DOI: 10.1182/Blood-2010-04-279125  0.383
2010 Barosi G, Gattoni E, Guglielmelli P, Campanelli R, Facchetti F, Fisogni S, Goldberg J, Marchioli R, Hoffman R, Vannucchi AM. Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition. American Journal of Hematology. 85: 616-9. PMID 20540156 DOI: 10.1002/Ajh.21754  0.45
2010 Araki H, Chute JP, Petro B, Halliday L, Hoffman R, Mahmud N. Bone marrow CD34+ cells expanded on human brain endothelial cells reconstitute lethally irradiated baboons in a variable manner. Leukemia & Lymphoma. 51: 1121-7. PMID 20470216 DOI: 10.3109/10428191003786774  0.425
2010 Cho SY, Xu M, Roboz J, Lu M, Mascarenhas J, Hoffman R. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Research. 70: 3402-10. PMID 20388788 DOI: 10.1158/0008-5472.Can-09-3977  0.415
2010 Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J, Mascarenhas J, Xu M, Hoffman R. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Experimental Hematology. 38: 472-80. PMID 20303384 DOI: 10.1016/J.Exphem.2010.03.005  0.325
2010 Ghinassi B, Martelli F, Verrucci M, D'Amore E, Migliaccio G, Vannucchi AM, Hoffman R, Migliaccio AR. Evidence for organ-specific stem cell microenvironments. Journal of Cellular Physiology. 223: 460-70. PMID 20112287 DOI: 10.1002/Jcp.22055  0.394
2010 Rondelli D, Boyer MW, Isola LM, Shore T, Bacigalupo A, Klisovic RB, Marchioli R, Goldberg JD, Hoffman R, Silverman LR. First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol. Journal of Clinical Oncology. 28: 6535-6535. DOI: 10.1200/Jco.2010.28.15_Suppl.6535  0.362
2010 Varricchio L, Masselli E, Migliaccio G, Whitsett C, Hoffman R, Migliaccio ARF. The A3669G Polymorphism of GR Is a Host Genetic Modifier Associated with Polycythemia Vera and Primary Myelofibrosis Blood. 116: 3067-3067. DOI: 10.1182/Blood.V116.21.3067.3067  0.387
2010 Iancu-Rubin C, Feller F, Gajzer D, Mascarenhas J, Hoffman R. Targeting Non-Histone Protein Acetylation Impairs Platelet Production During Normal Megakaryocytopoiesis. Blood. 116: 2610-2610. DOI: 10.1182/Blood.V116.21.2610.2610  0.401
2010 Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J, Chaurasia P, Mascarenhas J, Xu M, Hoffman R. Abstract LB-54: Interferon targets JAK2V617F positive hematopoietic progenitor cells and acts through the p38 MAP kinase pathway Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-54  0.367
2009 Sozer S, Ishii T, Fiel MI, Wang J, Wang X, Zhang W, Godbold J, Xu M, Hoffman R. Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo. Blood Cells, Molecules & Diseases. 43: 304-12. PMID 19762257 DOI: 10.1016/J.Bcmd.2009.08.005  0.426
2009 Wang X, Zhang W, Ishii T, Sozer S, Wang J, Xu M, Hoffman R. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Research. 69: 7612-8. PMID 19752087 DOI: 10.1182/Blood.V112.11.101.101  0.392
2009 Wang X, LeBlanc A, Gruenstein S, Xu M, Mascarenhas J, Panzera B, Wisch N, Parker C, Goldberg JD, Prchal J, Hoffman R, Najfeld V. Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. Experimental Hematology. 37: 1194-200. PMID 19615425 DOI: 10.1016/J.Exphem.2009.07.003  0.349
2009 Wang J, Ishii T, Zhang W, Sozer S, Dai Y, Mascarenhas J, Najfeld V, Zhao ZJ, Hoffman R, Wisch N, Xu M. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. Leukemia. 23: 1577-86. PMID 19387466 DOI: 10.1038/leu.2009.85  0.315
2009 Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 113: 5246-9. PMID 19293426 DOI: 10.1182/Blood-2008-11-191544  0.396
2009 Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y, Wisch N, Xu M. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 113: 5942-50. PMID 19196660 DOI: 10.1182/Blood-2008-09-179416  0.413
2009 Straneva JE, Briddell RA, Hui SL, Hoffman R. Serum from patients with various thrombopoietic disorders alters terminal cytoplasmic maturation of human megakaryocytes in vitro. European Journal of Haematology. 42: 293-297. PMID 2784391 DOI: 10.1111/J.1600-0609.1989.Tb00115.X  0.346
2009 Hexner E, Goldberg JD, Prchal JT, Demakos EP, Swierczek S, Weinberg RS, Tripodi J, Najfeld V, Carroll M, Marchioli R, Silverman LR, Hoffman R. A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC). Blood. 114: 754-754. DOI: 10.1182/Blood.V114.22.754.754  0.327
2009 Moliterno AR, Hexner E, Roboz GJ, Carroll M, Luger S, Mascarenhas J, Hoffman R, Bensen-Kennedy DM. An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: Update of 39 Enrolled Patients. Blood. 114: 753-753. DOI: 10.1182/Blood.V114.22.753.753  0.401
2009 Lu M, Zhang W, Wang J, Li Y, Wang X, Yoo D, Austin A, Mascarenhas J, Zhao ZJ, Hoffman R, Xu M. Treatment in Vitro with a Combination of Bcl-Xl Inhibitor-ABT-737 and a JAK2 Inhibitor Selectively Eliminates JAK2V617F MPN Progenitor Cells. Blood. 114: 752-752. DOI: 10.1182/Blood.V114.22.752.752  0.422
2009 Navada SC, Mascarenhas J, Najfeld V, Hoffman R. Effective Management of Patients with Leukemic Transformation of Myelofibrosis. Blood. 114: 4967-4967. DOI: 10.1182/Blood.V114.22.4967.4967  0.417
2009 Lu M, Zhang W, Yoo D, Berenzon D, Li Y, Wang X, Austin A, Mascarenhas J, Xu M, Hoffman R. Treatment with Pegylated Interferon Alpha 2a in Combination with the Bcl-Xl Inhibitor ABT-737 Specifically Targets JAK2V617F Positive Hematopoietic Progenitor Cells From Patients with Polycythemia Vera. Blood. 114: 3916-3916. DOI: 10.1182/Blood.V114.22.3916.3916  0.366
2009 Varricchio L, Noia AD, Alfani E, Stellacci E, Battistini A, Baldassarre Ad, Migliaccio G, Vannucchi AM, Rondelli D, Hoffman R, Migliaccio AR. Erythroblasts From Polycythemia Vera Patients Express the Dominant negative β Isoform of the Glucocorticoid Receptor. Blood. 114: 3899-3899. DOI: 10.1182/Blood.V114.22.3899.3899  0.367
2009 Araki H, Chute J, Petro B, Katayama N, Hoffman R, Mahmud N. Bone Marrow CD34+ Cells Expanded On Human Brain Endothelial Cells Reconstitutes Lethally Irradiated Baboons in a Variable Manner. Blood. 114: 3214-3214. DOI: 10.1182/blood.v114.22.3214.3214  0.319
2009 Mascarenhas J, Wang X, Rodriguez A, Xu M, Gorman E, Zhang W, Goldberg JD, Najfeld V, Hoffman R. A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF). Blood. 114: 308-308. DOI: 10.1182/Blood.V114.22.308.308  0.481
2009 Migliaccio G, Dell’Aversana C, Nebbioso A, Alfani E, arricchio L, Mai A, Chaurasia P, Hoffman R, Bieker JJ, Altucci L, Migliaccio AR. Ontogenic-Specific Increasesin HDAC1 Activity and Transcription Factor Association During the Maturation of Human Adult Erythroblasts in Vitro. Blood. 114: 1978-1978. DOI: 10.1182/Blood.V114.22.1978.1978  0.305
2009 Wang X, Zhang W, Austin A, Yoo D, Lu M, Xu M, Hoffman R. Sequential Treatment of CD34+ Cells From Patients with Primary Myelofibrosis with Chromatin Modifying Agents Alters the Behavior of JAK2V617F Positive NOD/SCID Marrow Repopulating Cells. Blood. 114: 1910-1910. DOI: 10.1182/Blood.V114.22.1910.1910  0.419
2008 Sozer S, Wang X, Zhang W, Fiel MI, Ishii T, Wang J, Wisch N, Xu M, Hoffman R. Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders. Blood Cells, Molecules & Diseases. 41: 284-91. PMID 18715806 DOI: 10.1016/J.Bcmd.2008.06.008  0.389
2008 Chunduri S, Gaitonde S, Ciurea SO, Hoffman R, Rondelli D. Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation. Haematologica. 93: 1593-5. PMID 18641018 DOI: 10.3324/Haematol.13203  0.349
2008 Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai LC, Akard LP, Hoffman R, Rondelli D. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. British Journal of Haematology. 141: 80-3. PMID 18324970 DOI: 10.1111/J.1365-2141.2008.07010.X  0.406
2008 Migliaccio AR, Martelli F, Verrucci M, Migliaccio G, Vannucchi AM, Ni H, Xu M, Jiang Y, Nakamoto B, Papayannopoulou T, Hoffman R. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Experimental Hematology. 36: 158-71. PMID 18206727 DOI: 10.1016/J.Exphem.2007.10.001  0.392
2008 Shah NP, Olszynski P, Sokol L, Verstovsek S, Hoffman R, List AF, Cortes J, Kantarjian HM, Gilliland DG, Clary DO, Bui LA, Wadleigh M. A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Blood. 112: 98-98. DOI: 10.1182/Blood.V112.11.98.98  0.366
2008 Cho SY, Roboz J, Xu M, Hoffman R. Primary Myelofibrosis Is Associated with Truncation of the Plasma Chemokine SDF-1 Blood. 112: 3731-3731. DOI: 10.1182/Blood.V112.11.3731.3731  0.348
2008 Ishii T, Wang J, Zhang W, Mascarenhas J, Dai Y, Najfeld V, Hoffman R, Wisch N, Xu M. Mast Cells Are Involved by the Malignant Process and Play An Important Role in the Pruritogenesis in Patients with Myeloproliferative Disorders Blood. 112: 3729-3729. DOI: 10.1182/Blood.V112.11.3729.3729  0.417
2008 Wang X, Leblanc A, Gruenstein S, Xu M, Wisch N, Hoffman R, Najfeld V. The Relationship Between Chromosomally Abnormal Hematopoiesis and the JAK2V617F Allele Burden in Patients (pts) with Ph-Negative Chronic Myeloproliferative Disorders (Ph-neg MPD) Blood. 112: 3106-3106. DOI: 10.1182/Blood.V112.11.3106.3106  0.334
2008 Sozer S, Fiel IM, Schiano T, Feller F, Mascarenhas J, Hoffman R. The JAK2V617F Mutation Is Present in the Liver Endothelial Cells of Patients with Budd-Chiari Syndrome Blood. 112: 2795-2795. DOI: 10.1182/Blood.V112.11.2795.2795  0.393
2008 Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai L, Akard LP, Hoffman R, Rondelli D. 303: Role of Extensive Splenomegaly in Patients with Myelofibrosis undergoing a Reduced Intensity Allogeneic Stem Cell Transplant Biology of Blood and Marrow Transplantation. 14: 112. DOI: 10.1016/J.Bbmt.2007.12.313  0.374
2007 Hoffman R, Rondelli D. Biology and treatment of primary myelofibrosis. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 346-54. PMID 18024650 DOI: 10.1182/Asheducation-2007.1.346  0.369
2007 Ishii T, Zhao Y, Sozer S, Shi J, Zhang W, Hoffman R, Xu M. Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. Experimental Hematology. 35: 1633-40. PMID 17764815 DOI: 10.1016/J.Exphem.2007.07.005  0.364
2007 Ishii T, Zhao Y, Shi J, Sozer S, Hoffman R, Xu M. T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation Leukemia. 21: 2433-2441. PMID 17713553 DOI: 10.1038/Sj.Leu.2404899  0.394
2007 Shi J, Zhao Y, Ishii T, Hu W, Sozer S, Zhang W, Bruno E, Lindgren V, Xu M, Hoffman R. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Research. 67: 6417-24. PMID 17616702 DOI: 10.1158/0008-5472.CAN-07-0572  0.323
2007 Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W, Bruno E, Barosi G, Xu M, Hoffman R. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 110: 986-93. PMID 17473062 DOI: 10.1182/Blood-2006-12-064626  0.392
2007 Hu WY, Zhao Y, Ishii T, Sozer S, Shi J, Zhang W, Bruno E, Hoffman R, Xu M. Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis. British Journal of Haematology. 137: 378-9. PMID 17408398 DOI: 10.1111/J.1365-2141.2007.06572.X  0.313
2007 Rosti V, Massa M, Vannucchi AM, Bergamaschi G, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Guglielmelli P, Bruno E, Xu M, Hoffman R, Barosi G, et al. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells, Molecules & Diseases. 38: 280-6. PMID 17350297 DOI: 10.1016/J.Bcmd.2007.01.003  0.395
2007 Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 64-72. PMID 17222772 DOI: 10.1016/J.Bbmt.2006.11.003  0.405
2007 Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, Mahmud N. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood. 109: 3570-8. PMID 17185465 DOI: 10.1182/blood-2006-07-035287  0.332
2007 Barosi G, Gattoni E, Barbui T, Vannucchi AM, Rambaldi A, Silverman L, Goldberg J, Marchioli R, Hoffman R. A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis. Blood. 110: 3540-3540. DOI: 10.1182/Blood.V110.11.3540.3540  0.351
2007 Sozer S, Ishii T, Zhang W, Wang J, Xu M, Hoffman R. Two Classes of Progenitor Cells in Patients with Myeloproliferative Disorders Are Capable of Generating JAK2V617F+CD31+CD144+ Endothelial Cells. Blood. 110: 261-261. DOI: 10.1182/Blood.V110.11.261.261  0.388
2007 Ciurea SO, Sadegi B, Wilbur A, Alagiozian-Angelova V, Gaitonde S, Dobogai LC, Akard LP, Hoffman R, Rondelli D. Is Splenectomy Necessary in Patients with Myelofibrosis and Extensive Splenomegaly Prior to Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning Regimens Blood. 110: 1091-1091. DOI: 10.1182/Blood.V110.11.1091.1091  0.372
2006 Ni H, Barosi G, Hoffman R. Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. American Journal of Clinical Pathology. 126: 241-7. PMID 16891200 DOI: 10.1309/4Ygked5Lwfw4Avdv  0.326
2006 Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 108: 3128-34. PMID 16757685 DOI: 10.1182/Blood-2006-04-017392  0.391
2006 Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA, Camoriano JK, Gisslinger H, ... ... Hoffman R, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 108: 1497-503. PMID 16675707 DOI: 10.1182/Blood-2006-03-009746  0.387
2006 Abbasian J, Mahmud D, Mahmud N, Chunduri S, Araki H, Reddy P, Hoffman R, Arpinati M, Ferrara JL, Rondelli D. Allogeneic T cells induce rapid CD34+ cell differentiation into CD11c+CD86+ cells with direct and indirect antigen-presenting function. Blood. 108: 203-8. PMID 16478883 DOI: 10.1182/Blood-2005-11-4330  0.403
2006 Araki H, Mahmud N, Milhem M, Nunez R, Xu M, Beam CA, Hoffman R. Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Experimental Hematology. 34: 140-9. PMID 16459182 DOI: 10.1016/J.EXPHEM.2005.10.002  0.369
2006 Ciurea SO, Mahmud N, Bruno E, Ishii T, Xu M, Hoffman R. Identification of the Origins and Characterization of the Consequences of Megakaryocytic Hyperplasia in Idiopathic Myelofibrosis. Blood. 108: 663-663. DOI: 10.1182/Blood.V108.11.663.663  0.397
2006 Campanelli R, Massa M, Rosti V, Bergamaschi G, Viarengo G, Marchetti M, Hoffman R, Barosi G. Reduced CD26 Dipeptidylpeptidase IV Membrane Expression and Activity of CD34+ Cells from Patients with Myelofibrosis with Myeloid Metaplasia. Blood. 108: 3617-3617. DOI: 10.1182/Blood.V108.11.3617.3617  0.388
2006 Ishii T, Bruno E, Zhao Y, Hoffman R, Xu M. Engraftment of Subpopulations of Hematopoietic Cells from Patients with Polycythemia Vera in NOD/SCID Mice. Blood. 108: 3593-3593. DOI: 10.1182/Blood.V108.11.3593.3593  0.423
2006 Araki H, Yoshinaga K, Hoffman R, Boccuni P, Mahmud N. Ex-Vivo Expansion of Marrow Repopulating Cells by Chromatin Modifying Agents Is Associated with Modulation of Expression of Genes Implicated in HSC Self-Renewal. Blood. 108: 1670-1670. DOI: 10.1182/Blood.V108.11.1670.1670  0.431
2006 Hoffman R. Searching for polycythemia vera's Holy Grail Blood. 108: 1792-1793. DOI: 10.1182/Blood-2006-07-031591  0.301
2006 Hoffman R, Xu M. Is bone marrow fibrosis the real problem Blood. 107: 3421-3422. DOI: 10.1182/Blood-2006-02-002683  0.325
2005 Barosi G, Hoffman R. Idiopathic myelofibrosis. Seminars in Hematology. 42: 248-58. PMID 16210038 DOI: 10.1053/j.seminhematol.2005.05.018  0.305
2005 Massa M, Rosti V, Ramajoli I, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Hoffman R, Barosi G. Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2–Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia Journal of Clinical Oncology. 23: 5688-5695. PMID 16110028 DOI: 10.1200/Jco.2005.09.021  0.389
2005 Ni H, Barosi G, Rondelli D, Hoffman R. Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis. American Journal of Clinical Pathology. 123: 833-9. PMID 15899773 DOI: 10.1309/7A5J-U9KJ-K89V-QPH9  0.329
2005 Xu M, Bruno E, Chao J, Huang S, Finazzi G, Fruchtman SM, Popat U, Prchal JT, Barosi G, Hoffman R. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases Blood. 105: 4508-4515. PMID 15705794 DOI: 10.1182/Blood-2004-08-3238  0.361
2005 Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP, Spivak JL, Douglas Smith B, Klingemann HG, Fruchtman S, Hoffman R. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia Blood. 105: 4115-4119. PMID 15671439 DOI: 10.1182/Blood-2004-11-4299  0.359
2005 Xu M, Bruno E, Chao J, Ni H, Lindgren V, Nunez R, Mahmud N, Finazzi G, Fruchtman SM, Popat U, Liu E, Prchal JT, Rondelli D, Barosi G, Hoffman R. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood. 105: 1699-705. PMID 15471948 DOI: 10.1182/Blood-2004-06-2485  0.421
2005 Ni H, Barosi G, Rondelli D, Hoffman R. Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis American Journal of Clinical Pathology. 123: 833-839. DOI: 10.1309/7A5Ju9Kjk89Vqph9  0.45
2005 Araki H, Mahmud N, Milhem M, Xu M, Hoffman R. Use of Chromatin Modifying Agents for Ex Vivo Expansion of Human Umbilical Cord Blood Stem Cells. Blood. 106: 4208-4208. DOI: 10.1182/Blood.V106.11.4208.4208  0.4
2005 Xu M, Bruno E, Ni H, Rosti V, Massa M, Barosi G, Hoffman R. SDF-1/CXCR4 Interactions in Idiopathic Myelofibrosis. Blood. 106: 3504-3504. DOI: 10.1182/Blood.V106.11.3504.3504  0.433
2005 Saraf S, Chen Y, Dobogai LC, Saunthararajah Y, Peace D, Hoffman R, Mahmud N, Chunduri S, Rondelli D. African American Patients with Multiple Myeloma Have Prolonged Responses after Autologous Stem Cell Transplantation. Blood. 106: 3131-3131. DOI: 10.1182/Blood.V106.11.3131.3131  0.374
2005 Massa M, Rosti V, Vannuccchi AM, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Guglielmelli P, Bruno E, Xu M, Hoffman R, Barosi G. Reduced Expression of CXCR4 on Circulating CD34+ Cells Is Associated with Hematopoietic Progenitor Cells (HPC) Mobilization in Patients with Myelofibrosis with Myeloid Metaplasia (MMM). Blood. 106: 258-258. DOI: 10.1182/Blood.V106.11.258.258  0.388
2005 Araki H, Hoffman R, Mahmud N. Different Histone Deacetylase Inhibitors Affect Distinct Cellular Targets within the Hierarchy of Hematopoietic Stem / Progenitor Cells. Blood. 106: 1721-1721. DOI: 10.1182/Blood.V106.11.1721.1721  0.427
2004 Oh IH, Fabry ME, Humphries RK, Pawliuk R, Leboulch P, Hoffman R, Nagel RL, Eaves C. Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells. Experimental Hematology. 32: 461-9. PMID 15145214 DOI: 10.1016/J.Exphem.2004.02.001  0.367
2004 Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y, Hoffman R. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood. 103: 4102-4110. PMID 14976039 DOI: 10.1182/Blood-2003-07-2431  0.41
2004 Huang S, Xu M, Bruno E, Barosi G, Prchal J, Hoffman R. HMGA2, a Member of the High Mobility Group Gene Family, Is Expressed at the Protein Level in Peripheral Blood CD34+ Cells of Patients with Idiopathic Myelofibrosis and Polycythemia Vera. Blood. 104: 798-798. DOI: 10.1182/Blood.V104.11.798.798  0.431
2004 Chunduri S, Jessop E, Dobogai LC, Peace D, Sanuthararajah Y, Chen Y, Mahmud N, Maynard V, Hoffman R, Rondelli D. Comparable Toxicity between Fludarabine/Full dose i.v. Busulfan and Fludarabine/Melphalan in Allogeneic PBSC Transplantation. Blood. 104: 5032-5032. DOI: 10.1182/Blood.V104.11.5032.5032  0.357
2004 Abbasian J, Mahmud N, Araki H, Bruno E, Arpinati M, Hoffman R, Rondelli D. In-Vitro and In-Vivo Effects of Autologous and Allogeneic Lymphocytes on Human Cord Blood CD34+ Cell Function. Blood. 104: 4962-4962. DOI: 10.1182/Blood.V104.11.4962.4962  0.402
2004 Araki H, Mahmud N, Milhem M, Patel HS, Nunez R, Bruno E, Hoffman R. CD34+CD90+ Cord Blood Cells Which Have Undergone Multiple Cell Divisions Retain Marrow Repopulating Potential. Blood. 104: 3228-3228. DOI: 10.1182/Blood.V104.11.3228.3228  0.383
2003 Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 102: 3865-70. PMID 12907443 DOI: 10.1182/Blood-2003-05-1738  0.354
2003 Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 101: 2999-3001. PMID 12480709 DOI: 10.1182/Blood-2002-06-1830  0.302
2002 Mahmud N, Weiss P, Li F, Hoffman R. Primate skeletal muscle contains cells capable of sustaining in vitro hematopoiesis Experimental Hematology. 30: 925-936. PMID 12160844 DOI: 10.1016/S0301-472X(02)00863-9  0.355
2002 Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology. 30: 42-8. PMID 11823036 DOI: 10.1016/S0301-472X(01)00769-X  0.338
2002 Hoffman R. Special Issue on Stem Cell Plasticity Experimental Hematology. 30: 847. DOI: 10.1016/S0301-472X(02)00891-3  0.328
2002 Hoffman R. Quality of life issues in patients with essential thrombocythemia and polycythemia vera. Seminars in Oncology. 29: 3-9. DOI: 10.1016/S0093-7754(02)70146-2  0.314
2001 Bartholomew A, Patil S, Mackay A, Nelson M, Buyaner D, Hardy W, Mosca J, Sturgeon C, Siatskas M, Mahmud N, Ferrer K, Deans R, Moseley A, Hoffman R, Devine SM. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Human Gene Therapy. 12: 1527-41. PMID 11506695 DOI: 10.1089/10430340152480258  0.362
2001 Gomes I, Sharma TT, Mahmud N, Kapp JD, Edassery S, Fulton N, Liang J, Hoffman R, Westbrook CA. Highly abundant genes in the transcriptosome of human and baboon CD34 antigen-positive bone marrow cells. Blood. 98: 93-9. PMID 11418467 DOI: 10.1182/Blood.V98.1.93  0.362
2001 Mahmud N, Devine SM, Weller KP, Parmar S, Sturgeon C, Nelson MC, Hewett T, Hoffman R. The relative quiescence of hematopoietic stem cells in nonhuman primates. Blood. 97: 3061-8. PMID 11342431 DOI: 10.1182/Blood.V97.10.3061  0.373
2001 Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C, Hewett T, Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, ... ... Hoffman R, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Experimental Hematology. 29: 244-55. PMID 11166464 DOI: 10.1016/S0301-472X(00)00635-4  0.401
2001 Sharma AK, Nelson MC, Brandt JE, Wessman M, Mahmud N, Weller KP, Hoffman R. Human CD34(+) stem cells express the hiwi gene, a human homologue of the Drosophila gene piwi. Blood. 97: 426-34. PMID 11154219 DOI: 10.1182/Blood.V97.2.426  0.414
2001 Westbrook C, Gomes I, Le T, Kapp J, Hoffman R. A cDNA data set for expression studies of hematopoietic stem cells: characterization and database mining Nature Genetics. 27: 95-95. DOI: 10.1038/87360  0.387
2000 Rosler E, Brandt J, Chute J, Hoffman R. Cocultivation of umbilical cord blood cells with endothelial cells leads to extensive amplification of competent CD34+CD38- cells. Experimental Hematology. 28: 841-852. PMID 10907646 DOI: 10.1016/S0301-472X(00)00177-6  0.42
2000 Alsayed Y, Modi S, Uddin S, Mahmud N, Druker BJ, Fish EN, Hoffman R, Platanias LC. All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cells. Experimental Hematology. 28: 826-32. PMID 10907644 DOI: 10.1016/S0301-472X(00)00170-3  0.304
2000 Stock W, Hoffman R. White blood cells 1: Non-malignant disorders Lancet. 355: 1351-1357. PMID 10776761 DOI: 10.1016/S0140-6736(00)02125-5  0.365
2000 Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, Overveld Wv, DeSimone J. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 96: 2379-2384. DOI: 10.1182/Blood.V96.7.2379.H8002379_2379_2384  0.323
2000 Rosler ES, Brandt JE, Chute J, Hoffman R. An in vivo competitive repopulation assay for various sources of human hematopoietic stem cells Blood. 96: 3414-3421. DOI: 10.1182/blood.v96.10.3414.h8003414_3414_3421  0.324
2000 Rosler ES, Brandt JE, Chute J, Hoffman R. An in vivo competitive repopulation assay for various sources of human hematopoietic stem cells Blood. 96: 3414-3421. DOI: 10.1182/Blood.V96.10.3414  0.434
1999 Platanias LC, Uddin S, Bruno E, Korkmaz M, Ahmad S, Alsayed Y, Van Den Berg D, Druker BJ, Wickrema A, Hoffman R. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Experimental Hematology. 27: 1315-21. PMID 10428508 DOI: 10.1016/S0301-472X(99)00060-0  0.362
1999 Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, Yeo EL, Schuh AC, Sutherland DR. CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Experimental Hematology. 27: 1282-1294. PMID 10428505 DOI: 10.1016/S0301-472X(99)00071-5  0.357
1999 Wickrema A, Chen F, Namin F, Yi T, Ahmad S, Uddin S, Chen YH, Feldman L, Stock W, Hoffman R, Platanias LC. Defective expression of the SHP-1 phosphatase in polycythemia vera. Experimental Hematology. 27: 1124-32. PMID 10390187 DOI: 10.1016/S0301-472X(99)00043-0  0.342
1999 Medin JA, Brandt JE, Rozler E, Nelson M, Bartholomew A, Li C, Turian J, Chute J, Chung T, Hoffman R. Ex vivo expansion and genetic marking of primitive human and baboon hematopoietic cells Annals of the New York Academy of Sciences. 872: 233-242. PMID 10372126 DOI: 10.1111/J.1749-6632.1999.Tb08468.X  0.403
1999 Hoffman R. Progress in the development of systems for in vitro expansion of human hematopoietic stem cells. Current Opinion in Hematology. 6: 184-191. PMID 10226740 DOI: 10.1097/00062752-199905000-00010  0.377
1999 Brandt JE, Bartholomew AM, Fortman JD, Nelson MC, Bruno E, Chen LM, Turian JV, Davis TA, Chute JP, Hoffman R. Ex vivo expansion of autologous bone marrow CD34(+) cells with porcine microvascular endothelial cells results in a graft capable of rescuing lethally irradiated baboons. Blood. 94: 106-113. DOI: 10.1182/Blood.V94.1.106.413K01_106_113  0.435
1998 Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan K, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Atkinson K, Reading C, Hoffman R, et al. Collection, Tumor Contamination, and Engraftment Kinetics of Highly Purified Hematopoietic Progenitor Cells to Support High Dose Therapy in Multiple Myeloma Blood. 91: 4489-4495. DOI: 10.1182/BLOOD.V91.12.4489.412K11_4489_4495  0.338
1997 Bazil V, Brandt JE, Hoffman R, Kaushansky K, Lansdorp PM, Eaves C, Torok-Storb B, Sharkis SJ, Papayannopoulou T. Resistance of human hematopoietic stem cells to a monoclonal antibody recognizing CD43 Stem Cells. 15: 13-19. PMID 9368320 DOI: 10.1002/Stem.5530150804  0.416
1996 Hoffman R, Murrav LJ, Young JC, Luens KM, Bruno E. Hierarchical structure of human megakaryocyte progenitor cells. Stem Cells (Dayton, Ohio). 14: 75-81. PMID 11012205 DOI: 10.1002/Stem.5530140709  0.428
1996 Srour EF, Bregni M, Traycoff CM, Agüero B, Kosak ST, Hoffman R, Siena S, Gianni AM. Long-term hematopoietic culture-initiating cells are more abundant in mobilized peripheral blood grafts than in bone marrow but have a more limited ex vivo expansion potential. Blood Cells, Molecules & Diseases. 22: 68-81. PMID 8807087 DOI: 10.1006/BCMD.1996.0010  0.302
1996 Murray LJ, Tsukamoto A, Hoffman R. CD34+Thy-1+Lin- stem cells from mobilized peripheral blood. Leukemia & Lymphoma. 22: 37-42, follow. 186, . PMID 8724526 DOI: 10.3109/10428199609051726  0.327
1996 Hoffman R, Tong J, Brandt J, Traycoff C, Bruno E, Srour EF, Gordon MS, Mcguire BW, Mcniece I. The in vitro and in vivo effects of stem cell factor on human hematopoiesis Stem Cells. 11: 76-82. PMID 7691331 DOI: 10.1002/Stem.5530110813  0.433
1996 Szilvassy S, Weller K, Chen B, Juttner C, Tsukamoto A, Hoffman R. Partially differentiated ex vivo expanded cells accelerate hematologic recovery in myeloablated mice transplanted with highly enriched long-term repopulating stem cells Blood. 88: 3642-3653. DOI: 10.1182/Blood.V88.9.3642.Bloodjournal8893642  0.398
1996 Bazil V, Brandt J, Chen S, Roeding M, Luens K, Tsukamoto A, Hoffman R. A monoclonal antibody recognizing CD43 (leukosialin) initiates apoptosis of human hematopoietic progenitor cells but not stem cells Blood. 87: 1272-1281. DOI: 10.1182/Blood.V87.4.1272.Bloodjournal8741272  0.416
1996 Gazitt Y, Tian E, Barlogie B, Reading C, Vesole D, Jagannath S, Schnell J, Hoffman R, Tricot G. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor Blood. 87: 805-811. DOI: 10.1182/BLOOD.V87.2.805.BLOODJOURNAL872805  0.343
1996 Szilvassy SJ, Weller KP, Lin W, Sharma AK, Ho ASY, Tsukamoto A, Hoffman R, Leiby KR, Gearing DP. Leukemia inhibitory factor upregulates cytokine expression by a murine stromal cell line enabling the maintenance of highly enriched competitive repopulating stem cells. Blood. 87: 4618-4628. DOI: 10.1182/Blood.V87.11.4618.Bloodjournal87114618  0.404
1995 Hoffman R. Human Hematopoietic Stem Cells: Potential Use as Tumor-Free Autografts After High-Dose Myeloablative Cancer Therapy The American Journal of the Medical Sciences. 309: 254-259. PMID 7733140 DOI: 10.1097/00000441-199530950-00004  0.394
1995 Orazi A, Gordon MS, John K, Sledge G, Neiman RS, Hoffman R. In vivo effects of recombinant human stem cell factor treatment. A morphologic and immunohistochemical study of bone marrow biopsies. American Journal of Clinical Pathology. 103: 177-184. PMID 7531939 DOI: 10.1093/Ajcp/103.2.177  0.436
1995 Berliner N, Hsing A, Graubert T, Sigurdsson F, Zain M, Bruno E, Hoffman R. Granulocyte colony-stimulating factor induction of normal human bone marrow progenitors results in neutrophil-specific gene expression Blood. 85: 799-803. PMID 7530510 DOI: 10.1182/Blood.V85.3.799.Bloodjournal853799  0.376
1995 Fraser C, Kaneshima H, Hansteen G, Kilpatrick M, Hoffman R, Chen B. Human allogeneic stem cell maintenance and differentiation in a long- term multilineage SCID-hu graft Blood. 86: 1680-1693. DOI: 10.1182/BLOOD.V86.5.1680.BLOODJOURNAL8651680  0.315
1995 Bazil V, Brandt J, Tsukamoto A, Hoffman R. Apoptosis of human hematopoietic progenitor cells induced by crosslinking of surface CD43, the major sialoglycoprotein of leukocytes Blood. 86: 502-511. DOI: 10.1182/Blood.V86.2.502.Bloodjournal862502  0.382
1995 Gazitt Y, Reading C, Hoffman R, Wickrema A, Vesole D, Jagannath S, Condino J, Lee B, Barlogie B, Tricot G. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells Blood. 86: 381-389. DOI: 10.1182/BLOOD.V86.1.381.BLOODJOURNAL861381  0.351
1994 Cornetta K, Moore A, Leemhuis T, Moen RC, Tricot G, Leibowitz D, Hoffman R. Retroviral mediated gene transfer in chronic myelogenous leukaemia. British Journal of Haematology. 87: 308-316. PMID 7947272 DOI: 10.1111/J.1365-2141.1994.Tb04914.X  0.345
1994 Brandt JE, Bhalla K, Hoffman R. Effects of interleukin-3 and c-kit ligand on the survival of various classes of human hematopoietic progenitor cells. Blood. 83: 1507-1514. DOI: 10.1182/Blood.V83.6.1507.Bloodjournal8361507  0.379
1993 Leemhuis T, Leibowitz D, Cox G, Silver R, Srour E, Tricot G, Hoffman R. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow Blood. 81: 801-807. DOI: 10.1182/Blood.V81.3.801.Bloodjournal813801  0.318
1993 Srour E, Brandt J, Briddell R, Grigsby S, Leemhuis T, Hoffman R. Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro Blood. 81: 661-669. DOI: 10.1182/Blood.V81.3.661.Bloodjournal813661  0.306
1992 Jayaram HN, Lapis E, Tricot G, Kneebone P, Paulik E, Zhen W, Engeler GP, Hoffman R, Weber G. Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. International Journal of Cancer. 51: 182-8. PMID 1568787 DOI: 10.1002/Ijc.2910510204  0.329
1992 Long MW, Briddell R, Walter AW, Bruno E, Hoffman R. Human hematopoietic stem cell adherence to cytokines and matrix molecules. The Journal of Clinical Investigation. 90: 251-5. PMID 1378855 DOI: 10.1172/Jci115844  0.354
1992 Srour EF, Zanjani ED, Brandt JE, Leemhuis T, Briddell RA, Heerema NA, Hoffman R. Sustained human hematopoiesis in sheep transplanted in utero during early gestation with fractionated adult human bone marrow cells. Blood. 79: 1404-1412. DOI: 10.1182/Blood.V79.6.1404.1404  0.403
1992 Brandt J, Briddell R, Srour E, Leemhuis T, Hoffman R. Role of c-kit ligand in the expansion of human hematopoietic progenitor cells Blood. 79: 634-641. DOI: 10.1182/Blood.V79.3.634.634  0.37
1992 Briddell R, Broudy V, Bruno E, Brandt J, Srour E, Hoffman R. Further phenotypic characterization and isolation of human hematopoietic progenitor cells using a monoclonal antibody to the c-kit receptor Blood. 79: 3159-3167. DOI: 10.1182/Blood.V79.12.3159.Bloodjournal79123159  0.41
1991 Srour EF, Leemhuis T, Brandt JE, Van Besien K, Hoffman R. Simultaneous use of rhodamine 123, phycoerythrin, Texas red, and allophycocyanin for the isolation of human hematopoietic progenitor cells Cytometry. 12: 179-183. PMID 2049974 DOI: 10.1002/Cyto.990120213  0.342
1990 Weber G, Yamaji Y, Olah E, Natsumeda Y, Jayaram HN, Lapis E, Zhen WN, Prajda N, Hoffman R, Tricot GJ. Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin. Advances in Enzyme Regulation. 28: 335-56. PMID 2576178 DOI: 10.1016/0065-2571(89)90080-0  0.387
1990 Friend PJ, McCarthy LJ, Filo RS, Leapman SB, Pescovitz MD, Lumeng L, Pound D, Arnold K, Hoffman R, McFarland JG, Aster RH. Transmission of Idiopathic (Autoimmune) Thrombocytopenic Purpura by Liver Transplantation The New England Journal of Medicine. 323: 807-811. PMID 2392133 DOI: 10.1056/Nejm199009203231207  0.314
1990 Dayton MA, Besien KV, Tricot G, Hoffman R. Preleukemic state preceding adult acute lymphoblastic leukemia. The American Journal of Medicine. 89: 657-662. PMID 2239985 DOI: 10.1016/0002-9343(90)90186-H  0.334
1990 Tricot G, Jayaram HN, Weber G, Hoffman R. Tiazofurin: biological effects and clinical uses. International Journal of Cell Cloning. 8: 161-70. PMID 2189014 DOI: 10.1002/Stem.5530080303  0.386
1990 Brandt J, Srour EF, van Besien K, Briddell RA, Hoffman R. Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow. The Journal of Clinical Investigation. 86: 932-41. PMID 1697607 DOI: 10.1172/Jci114795  0.329
1989 Weber G, Jayaram HN, Lapis E, Natsumeda Y, Yamada Y, Yamaji Y, Tricot GJ, Hoffman R. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia. Advances in Enzyme Regulation. 27: 405-33. PMID 2907968 DOI: 10.1016/0065-2571(88)90029-5  0.4
1989 Nichols CR, Tricot G, Williams SD, Besien Kv, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. Journal of Clinical Oncology. 7: 932-939. PMID 2544687 DOI: 10.1200/Jco.1989.7.7.932  0.323
1989 Briddell R, Brandt J, Straneva J, Srour E, Hoffman R. Characterization of the human burst-forming unit-megakaryocyte Blood. 74: 145-151. DOI: 10.1182/Blood.V74.1.145.145  0.354
1988 Silva MAPd, Heerema N, Schwenk GR, Hoffman R. Evidence for the clonal nature of hypereosinophilic syndrome Cancer Genetics and Cytogenetics. 32: 109-115. PMID 3355992 DOI: 10.1016/0165-4608(88)90317-2  0.316
1988 Lu L, Briddell RA, Graham CD, Brandt JE, Bruno E, Hoffman R. Effect of recombinant and purified human haematopoietic growth factors on in vitro colony formation by enriched populations of human megakaryocyte progenitor cells British Journal of Haematology. 70: 149-156. PMID 3263879 DOI: 10.1111/J.1365-2141.1988.Tb02456.X  0.307
1988 Hoffman R, Lu L, Jansen J, Bruno E, Brandt J, Boral L, Cheung K. Influence of T lymphocytes on hematopoiesis in a patient with T cell hypoplasia. American Journal of Hematology. 27: 118-24. PMID 3257644 DOI: 10.1002/Ajh.2830270210  0.397
1988 Srivastava A, Boswell HS, Heerema NA, Nahreini P, Lauer RC, Antony AC, Hoffman R, Tricot GJ. KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. Cancer Genetics and Cytogenetics. 35: 61-71. PMID 3180012 DOI: 10.1016/0165-4608(88)90123-9  0.375
1988 Brandt J, Baird N, Lu L, Srour E, Hoffman R. Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. The Journal of Clinical Investigation. 82: 1017-27. PMID 3047166 DOI: 10.1172/Jci113658  0.358
1987 Akard LP, Brandt J, Lu L, Jansen J, Hoffman R. Chronic T cell lymphoproliferative disorder and pure red cell aplasia: Further characterization of cell-mediated inhibition of erythropoiesis and clinical response to cytotoxic chemotherapy The American Journal of Medicine. 83: 1069-1074. PMID 3140658 DOI: 10.1016/0002-9343(87)90943-0  0.402
1987 McGuire WA, Yang HH, Bruno E, Brandt J, Briddell R, Coates TD, Hoffman R. Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. The New England Journal of Medicine. 317: 1004-8. PMID 3116428 DOI: 10.1056/Nejm198710153171606  0.413
1985 Hoffman R, Zaknoen S, Yang HH, Bruno E, LoBuglio AF, Arrowsmith JB, Prchal JT. An Antibody Cytotoxic to Megakaryocyte Progenitor Cells in a Patient with Immune Thrombocytopenic Purpura The New England Journal of Medicine. 312: 1170-1174. PMID 4039036 DOI: 10.1056/Nejm198505023121807  0.341
1985 Schreeder MT, Prchal JT, Parmley RT, Carroll AJ, Gewirtz AM, Hoffman R. An acute myeloproliferative disorder characterized by myelofibrosis and blast cells that express phenotypic properties associated with multiple hematopoietic lineages. American Journal of Clinical Pathology. 83: 114-121. PMID 4038430 DOI: 10.1093/Ajcp/83.1.114  0.387
1985 Gewirtz AM, Hoffman R, Gardner FK. Current considerations of the etiology of aplastic anemia Critical Reviews in Oncology Hematology. 4: 1-30. PMID 3902262 DOI: 10.1016/S1040-8428(85)80018-4  0.373
1984 Lutton JD, Ibraham NG, Hoffman R, Ritchey AK, Levere RD. Sideroblastic anemia: differences in bone marrow erythroid colony (CFUE) growth responses to erythropoietin in plasma clot and methylcellulose cultures. American Journal of Hematology. 16: 219-226. PMID 6711554 DOI: 10.1002/Ajh.2830160303  0.335
1984 Nieneltow M, Cooper M, Breg WR, Hoffman R. Evidence for the clonal origin of acquired hypomegakaryocytic thrombocytopenic purpura from a sex chromosome mosaic Cancer Genetics and Cytogenetics. 12: 261-265. PMID 6539163 DOI: 10.1016/0165-4608(84)90038-4  0.355
1984 Frei-Lahr D, Barton J, Hoffman R, Burkett L, Prchal J. Blastic transformation of essential thrombocythemia: dual expression of myelomonoblastic/megakaryoblastic phenotypes Blood. 63: 866-872. DOI: 10.1182/BLOOD.V63.4.866.BLOODJOURNAL634866  0.32
1984 Frei-Lahr D, Barton J, Hoffman R, Burkett L, Prchal J. Blastic transformation of essential thrombocythemia: dual expression of myelomonoblastic/megakaryoblastic phenotypes Blood. 63: 866-872. DOI: 10.1182/blood.v63.4.866.866  0.32
1983 Hoffman R, McPhedran P, Benz EJ, Duffy TP. Isoniazid-induced pure red cell aplasia. The American Journal of the Medical Sciences. 286: 2-9. PMID 6869413 DOI: 10.1097/00000441-198307000-00001  0.398
1983 Dainiak N, Kulkarni V, Howard D, Kalmanti M, Dewey MC, Hoffman R. Mechanisms of abnormal erythropoiesis in malignancy Cancer. 51: 1101-1106. PMID 6821869 DOI: 10.1002/1097-0142(19830315)51:6<1101::Aid-Cncr2820510622>3.0.Co;2-G  0.368
1983 Gewirtz AM, Stewart AF, Vignery A, Hoffman R. Hypercalcaemia complicating acute myelogenous leukaemia: a syndrome of multiple aetiologies. British Journal of Haematology. 54: 133-140. PMID 6573910 DOI: 10.1111/J.1365-2141.1983.Tb02075.X  0.336
1982 Gewirtz A, Burger D, Rado T, Benz EJ, Hoffman R. Constitutive expression of platelet glycoproteins by the human leukemia cell line K562 Blood. 60: 785-789. DOI: 10.1182/Blood.V60.3.785.785  0.333
1982 Tonkonow B, Hoffman R, Burger D, Elder J, Mazur E, Murnane M, Benz EJ. Differing responses of globin and glycophorin gene expression to hemin in the human leukemia cell line K562 Blood. 59: 738-746. DOI: 10.1182/Blood.V59.4.738.Bloodjournal594738  0.349
1981 Mazur EM, Hoffman R, Bruno E. Regulation of human megakaryocytopoiesis. An in vito analysis. Journal of Clinical Investigation. 68: 733-741. PMID 7276169 DOI: 10.1172/Jci110309  0.374
1981 Hoffman R, Mazur E, Bruno E, Floyd V. Assay of an activity in the serum of patients with disorders of thrombopoiesis that stimulates formation of megakaryocytic colonies. The New England Journal of Medicine. 305: 533-538. PMID 6973086 DOI: 10.1056/Nejm198109033051001  0.343
1981 Hoffman R, Dainiak N, Floyd V, Ritchey AK, Mazur E. Erythropoiesis during an erythroblastic transformation of chronic myelocytic leukemia. Cancer. 47: 720-723. PMID 6939475 DOI: 10.1002/1097-0142(19810215)47:4<720::Aid-Cncr2820470416>3.0.Co;2-H  0.377
1981 Ritchey AK, Daniak N, Hoffman R, Komp P. 862 In Vitro Studies Of The Pathogenesis Of Transient Erythroblastopenia Of Childhood (Tec) Pediatric Research. 15: 586-586. DOI: 10.1203/00006450-198104001-00887  0.418
1981 Ritchey A, Hoffman R, Coupal E, Floyd V, Pearson H, Forget B. Imbalanced globin chain synthesis in cultured erythroid progenitor cells from thalassemic bone marrow and peripheral blood. Blood. 57: 788-793. DOI: 10.1182/Blood.V57.4.788.788  0.323
1980 Dainiak N, Hardin J, Floyd V, Callahan M, Hoffman R. Humoral suppression of erythropoiesis in systemic lupus erythematosus (SLE) and rheumatoid arthritis The American Journal of Medicine. 69: 537-544. PMID 7424943 DOI: 10.1016/0002-9343(80)90464-7  0.402
1980 Clyne LP, Dainiak N, Hoffman R, Hardin J. In vitro correction of anticoagulant activity and specific clotting factor assays in SLE Thrombosis Research. 18: 643-655. PMID 7414552 DOI: 10.1016/0049-3848(80)90219-4  0.301
1980 Dainiak N, Hoffman R, Ritchey AK, Floyd V, Callahan M. In vitro steroid sensitivity testing: A possible means to predict response to therapy in primary hypoproliferative anemia American Journal of Hematology. 9: 401-412. PMID 7211834 DOI: 10.1002/Ajh.2830090407  0.391
1980 Benz EJ, Murnane MJ, Tonkonow BL, Berman BW, Mazur EM, Cavallesco C, Jenko T, Snyder EL, Forget BG, Hoffman R. Embryonic-fetal erythroid characteristics of a human leukemic cell line. Proceedings of the National Academy of Sciences of the United States of America. 77: 3509-13. PMID 6932034 DOI: 10.1073/Pnas.77.6.3509  0.338
1979 Hoffman R, Dainiak N, Sibrack L, Pober JS, Waldron JA. Antibody-mediated aplastic anemia and diffuse fasciitis. The New England Journal of Medicine. 300: 718-21. PMID 763302 DOI: 10.1056/Nejm197903293001307  0.349
1979 Hoffman R, Murnane M, Benz EJ, Prohaska R, Floyd V, Dainiak N, Forget B, Furthmayr H. Induction of erythropoietic colonies in a human chronic myelogenous leukemia cell line Blood. 54: 1182-1187. DOI: 10.1182/Blood.V54.5.1182.Bloodjournal5451182  0.378
1979 Ritchey A, Hoffman R, Dainiak N, McIntosh S, Weininger R, Pearson H. Antibody-mediated acquired sideroblastic anemia: response to cytotoxic therapy. Blood. 54: 734-741. DOI: 10.1182/Blood.V54.3.734.Bloodjournal543734  0.345
1979 Dainiak N, Hoffman R, Lebowitz A, Solomon L, Maffei L, Ritchey K. Erythropoietin-dependent primary pure erythrocytosis Blood. 53: 1076-1084. DOI: 10.1182/Blood.V53.6.1076.Bloodjournal5361076  0.373
1978 Meyer RJ, Hoffman R, Zanjani ED. Autoimmune hemolytic anemia and periodic pure red cell aplasia in systemic lupus erythematosus The American Journal of Medicine. 65: 342-345. PMID 686017 DOI: 10.1016/0002-9343(78)90829-X  0.377
1978 Dainiak N, Hoffman R, Maffei LA, Forget BG. Potentiation of human erythropoiesis in vitro by thyroid hormone. Nature. 272: 260-2. PMID 628452 DOI: 10.1038/272260A0  0.331
1978 Littman BH, Cooke CL, Hoffman R. Hypogammaglobulinemia followed by aplastic anemia with suppressor lymphocytes: a case report. Clinical Immunology and Immunopathology. 10: 344-349. PMID 307476 DOI: 10.1016/0090-1229(78)90191-5  0.362
1978 Hoffman R, Kopel S, Hsu S, Dainiak N, Zanjani E. T cell chronic lymphocytic leukemia: presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro Blood. 52: 255-260. DOI: 10.1182/Blood.V52.1.255.Bloodjournal521255  0.399
1977 Zanjani ED, Lutton JD, Hoffman R, Wasserman LR. Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin Journal of Clinical Investigation. 59: 841-848. PMID 853125 DOI: 10.1172/Jci108706  0.36
1977 Hoffman R, Zanjani ED, Lutton JD, Zalusky R, Wasserman LR. Suppression of erythroid-colony formation by lymphocytes from patients with aplastic anemia. The New England Journal of Medicine. 296: 10-3. PMID 830263 DOI: 10.1056/Nejm197701062960103  0.396
1977 Kaffe S, Hsu LYF, Hoffman R, Hirschhorn K. ASSOCIATION OF 5q- AND REFRACTORY ANEMIA Pediatric Research. 11: 458-458. DOI: 10.1203/00006450-197704000-00531  0.339
1976 Hoffman R, Zanjani ED, Vila J, Zalusky R, Lutton JD, Wasserman LR. Diamond Blackfan syndrome: lymphocyte mediated suppression of erythropoiesis Science. 193: 899-900. PMID 986086 DOI: 10.1126/Science.986086  0.378
Show low-probability matches.